The Scottish Medicines Consortium (SMC) has made decisions on three products.
Xultophy (insulin degludec/liraglutide) from Novo Nordisk (NOV: N), Zytiga (abiraterone acetate) from Janssen, a unit of Johnson & Johnson (NYSE: JNJ), and Xofigo (radium-223 dichloride) from Bayer (BAYN: DE)) have all been given the green light by the SMC.
Xultophy is recommended for use in adults with type 2 diabetes, uncontrolled on basal insulin analogues and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin to obtain glucose control.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze